Table 4. Composition of the prostate prognosis tissue microarray.
| No. of patients (%) | ||
|---|---|---|
| Study cohort on TMA | Biochemical relapse among categories | |
| (n = 17,747) | ||
| Follow-up (mo) | ||
| n | 14667 (82.6%) | 3612 (24.6%) |
| Mean | 56.3 | — |
| Median | 48 | — |
| Age (y) | ||
| ≤50 | 433 (2.4%) | 66 (15.2%) |
| 51-59 | 4341 (24.5%) | 839 (19.3%) |
| 60-69 | 9977 (56.4%) | 2073 (20.8%) |
| ≥70 | 2936 (16.6%) | 634 (21.6%) |
| Pretreatment PSA (ng/ml) | ||
| <4 | 2225 (12.6%) | 313 (14.1%) |
| 4–10 | 10520 (59.6%) | 1696 (16.1%) |
| 10–20 | 3662 (20.8%) | 1043 (28.5%) |
| >20 | 1231 (7%) | 545 (44.3%) |
| pT stage (AJCC 2002) | ||
| pT2 | 11518 (65.2%) | 1212 (10.5%) |
| pT3a | 3842 (21.7%) | 1121 (29.2%) |
| pT3b | 2233 (12.6%) | 1213 (54.3%) |
| pT4 | 85 (0.5%) | 63 (74.1%) |
| Gleason grade | ||
| ≤3+3 | 3570 (18.1%) | 264 (7.4%) |
| 3+4 | 9336 (47.4%) | 1436 (15.4%) |
| 3+4 Tert.5 | 1697 (8.6%) | 165 (9.7%) |
| 4+3 | 2903 (14.7%) | 683 (23.5%) |
| 4+3 Tert.5 | 1187 (6%) | 487 (41%) |
| ≥4+4 | 999 (5.1%) | 531 (53.2%) |
| pN stage | ||
| pN0 | 10636 (89.4%) | 2243 (21.1%) |
| pN+ | 1255 (10.6%) | 700 (55.8%) |
| Surgical margin | ||
| Negative | 14297 (80.8%) | 2307 (16.1%) |
| Positive | 3388 (19.2%) | 1304 (38.5%) |
NOTE: Numbers do not always add up to 17,747 in the different categories because of cases with missing data.
Abbreviation: AJCC, American Joint Committee on Cancer.